You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The final decision includes some changes, most notably removing requirements for guideline inclusion, but retains its technical performance benchmarks.
The firm will scale US-based testing capacity for its LiquidHallmark liquid biopsy assay, which uses amplicon-based technology to detect cancer-related mutations.
Amid increasing spending on genetic testing, there are more opportunities for bad actors to implement interstate, fraudulent billing schemes, according to OIG.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The companies will work with labs to improve payors' understanding of the costs of performing PD-L1 testing and the value it provides to patient care.
New CMS billing rules and the rise of COVID-19 case numbers makes managing SARS-CoV-2 test turnaround times even more urgent for clinical laboratories.
The company is drawing on its previous experience developing and commercializing its HIV self-test to make progress on a test that could be used for three different indications.
The company's AlloSure Kidney test received coverage, along with its AlloSure Heart test when used with the firm's AlloMap test.
Novitas added multiple leukemia biomarkers to its coverage determination, as well as the ThyGeNEXT molecular panel.
The COVID-19 pandemic is the highest priority for most, but laboratory organizations are also looking ahead with longer-term goals for the new presidency.